Announcement of The Shaw Laureates 2025
HONG KONG, May 27, 2025 /PRNewswire/ --
The Shaw Prize in Astronomy is awarded in equal shares to
John Richard Bond
Professor, Canadian Institute for Theoretical Astrophysics and University Professor, University of Toronto, Canada and
George Efstathiou
Professor of Astrophysics, University of Cambridge, United Kingdom
for their pioneering research in cosmology, in particular for their studies of fluctuations in the cosmic microwave background. Their predictions have been verified by an armada of ground-, balloon- and space-based instruments, leading to precise determinations of the age, geometry, and mass-energy content of the universe.
The Shaw Prize in Life Science and Medicine is awarded to
Wolfgang Baumeister
Director Emeritus and Scientific Member, Max Planck Institute of Biochemistry, Germany
for his pioneering development and use of cryogenic-electron tomography (cryo-ET), an imaging technique that enables three-dimensional visualisation of biological samples, including proteins, macromolecular complexes, and cellular compartments as they exist in their natural cellular settings.
The Shaw Prize in Mathematical Sciences is awarded to
Kenji Fukaya
Professor, Beijing Institute of Mathematical Sciences and Applications and the Yau Mathematical Sciences Center, Tsinghua University, PRC
for his pioneering work on symplectic geometry, especially for envisioning the existence of a category — nowadays called the Fukaya category — consisting of Lagrangians on a symplectic manifold, for leading the monumental task of constructing it, and for his subsequent ground-breaking and impactful contributions to symplectic topology, mirror symmetry, and gauge theory.
Tuesday, 27 May 202 5. At today's press conference in Hong Kong, The Shaw Prize Foundation announced the Shaw Laureates for 2025. Information was posted on the website www.shawprize.org at Hong Kong time 15:30 (GMT 07:30).
The Shaw Prize consists of three annual prizes: Astronomy, Life Science and Medicine, and Mathematical Sciences, each bearing a monetary award of US$1.2 million. This will be the twenty-second year that the Prize has been awarded and the presentation ceremony is scheduled for Tuesday, 21 October 2025 in Hong Kong.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
Korea Herald
2 days ago
- Korea Herald
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink ® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink ® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink ® Reveal. Olink ® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink ® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink ® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink ® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink ® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink ® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Korea Herald
3 days ago
- Korea Herald
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62 nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile. IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care. At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN," said Prof. Barratt. "We're excited to see how the upcoming Phase 3 trials will further define its role." The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks.
